Researchers have developed a novel algorithm, the variational entanglement witness (VEW), enhancing quantum computers’ understanding and safeguarding of quantum entanglement. The VEW algorithm allows precise detection of entangled states, overcoming limitations of traditional methods in distinguishing them from separable subspaces. The study

Microsoft is a key player in the competitive AI landscape, actively engaging in strategic collaborations. The AI Infrastructure Partnership, supported by Microsoft, Nvidia, and others, aims to revolutionize AI infrastructure with a potential $100 billion investment. Microsoft leverages AI across cloud computing,

The radiopharmaceuticals market is undergoing a transformation driven by technology and sustainability, with significant growth expected through 2025 and beyond. Key innovations include AI-driven analytics and automation, enhancing diagnostic precision and patient outcomes. New isotopes like Fluorine-18 and Lutetium-177 are gaining prominence

Classiq Technologies, with Sumitomo Corporation and Mizuho–DL Financial Technology, achieves a 95% compression of quantum circuits in Monte Carlo simulations for credit portfolio risk management. This breakthrough significantly enhances efficiency in calculating Value at Risk (VaR), a critical finance metric, overcoming the

Omaha is introducing a groundbreaking proton therapy facility at the Buffett Cancer Center, enhancing precision medicine. Proton therapy offers precise targeting of cancer cells, minimizing damage to surrounding healthy tissues and reducing side effects. This treatment is particularly promising for tumors near

Bladder cancer, known for its recurrence, may see improved treatment through a repurposed tuberculosis vaccine. The Bacillus Calmette-Guérin (BCG) vaccine has long been used against non-muscle invasive bladder cancer (NMIBC) to prevent recurrence. Researchers in Barcelona are testing a newer tuberculosis vaccine,

Foghorn Therapeutics showcases its innovative cancer treatments at the 2025 AACR Meeting. FHD-909 targets SMARCA4 mutated non-small cell lung cancer (NSCLC) with selective SMARCA2 inhibition. First-in-class strategy aims to inhibit vital proteins necessary for tumor growth, showing promise in Phase 1 trials.

Rakovina Therapeutics, based in Vancouver, is revolutionizing oncology by integrating artificial intelligence (AI) with cancer therapy precision. AI-driven advancements have led to the creation of PARP1-selective inhibitors targeting brain tumors, overcoming the blood-brain barrier challenge. Rakovina utilizes Deep Docking technology, allowing AI

Cancer Action Day in Maine unites survivors, caregivers, and volunteers to advocate for transformative cancer care legislation. The focus is on expanding biomarker testing, which enables personalized cancer treatments, and increasing tobacco taxes by $1. Sharon Dow embodies personal advocacy, fighting for